Choice Institutional Equities has reiterated a 'Buy' rating on Narayana Hrudayalaya with a target price of ₹2,500, following the company's strong Q2 FY27 earnings. While growth in the integrated hospital-insurance model and international assets remains a highlight, investors should consider the challenges of the UK business turnaround and a significant multi-year expansion plan.
Choice Institutional Equities has maintained a 'Buy' rating on Narayana Hrudayalaya, setting a target price of ₹2,500 per share. This update follows the company’s recent second-quarter earnings announcement, where it reported consolidated operating revenue of ₹28,440 million, marking a 73% increase compared to the same period last year.
The brokerage's positive outlook is driven by the company’s strategy of integrating hospitals, clinics, and insurance services into one ecosystem. This model aims to create a competitive advantage in the healthcare sector. A key pillar of this growth plan is the recovery of international operations, particularly in the Cayman Islands, alongside an ongoing effort to improve efficiency in the newly integrated United Kingdom assets.
From a financial standpoint, the company reported an operating profit, or EBITDA, of ₹6,054 million for the quarter ending September 2026, translating to a margin of 21.3%. Profit after tax was recorded at ₹3,012 million. The company has also made progress on its balance sheet, with the net debt-to-equity ratio improving to 0.38x as of September 30, 2026, compared to 0.42x in the previous quarter.
However, investors should be aware of specific business risks when evaluating the company. The integration of the UK operations is a complex, long-term project. Management has previously noted that this turnaround could take five to seven years to fully mature. Delays in securing contracts with the National Health Service (NHS) in the UK could affect these timelines. Furthermore, the company carries foreign currency debt, specifically USD 114 million and GBP 150 million, which exposes the balance sheet to fluctuations in currency exchange rates.
Additionally, the company is in the middle of an ambitious growth phase, with plans to spend ₹30 billion on capital projects through fiscal year 2030. While this expansion aims to increase its footprint of over 6,100 beds across its facilities, the sheer size of this investment brings execution risks. The ability to manage this heavy spending while protecting profit margins in a competitive healthcare environment will be a critical factor for the company’s long-term performance.
The next steps for investors will be to monitor the pace of the UK operations' turnaround and the company's ability to maintain its margin profile despite the large capital spending plan. Consistent updates on debt management and project commissioning will also be important indicators of the company’s operational health in the coming quarters.